“Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis” (2007) Reumatismo, 59(1), pp. 32–37. doi:10.4081/reumatismo.2007.32.